Evidence map›Paper›PMID 38383835›Full record

ArticleBiochemical genetics2024

Analysis of the Molecular Mechanism of Xueshuantong in the Treatment of Wet Age-Related Macular Degeneration (AMD) Using GEO Datasets, Network Pharmacology, and Molecular Docking.

Ling Wang, Chaoyu Wang, Liangpin Li, Xueyan Zhou, Xia Hua, Xiaoyong Yuan

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Ling Wang *Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, 300020, China.
Chaoyu Wang *Department of Pediatric Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300052, China.
Liangpin LiClinical College of Ophthalmology, Tianjin Medical University, Tianjin, 300020, China.
Xueyan ZhouDepartment of Ophthalmology, The First People's Hospital of Xianyang City, Xianyang, 712000, China.
Xia HuaAier Eye Institute, Changsha, 410015, China. cathayhuaxia@163.com.
Xiaoyong YuanClinical College of Ophthalmology, Tianjin Medical University, Tianjin, 300020, China. yuanxy_cn@hotmail.com.
Tianjin Medical University · CNHe Eye Hospital · CNTianjin Medical University Cancer Institute and Hospital · CNTianjin Medical University Eye Hospital · CNXian Yang Central Hospital · CN

Funding

National Natural Science Foundation of China 81870638National Natural Science Foundation of China No. 81670817
6 · The paper itself

Abstract

At present, the main treatment method for wet AMD is single anti-VEGF therapy, which can require multiple injections, is costly and may have poor efficacy. Studies and clinical experiments have shown that the oral Chinese medicine Xueshuantong combined with anti-VEGF therapy is more effective, and this study aims to explore the molecular mechanism. The TCMSP database was used to identify the main Xueshuantong components. The PubChem database and SWISS Target Prediction data were used to find the SMILES molecular formulas of compounds and corresponding target genes and disease-related genes were searched using the GEO, DisGeNET, and GeneCards databases. Venny was used to identify the intersecting wet AMD-related genes and Xueshuantong targets and Cytoscape software was used to construct direct links between the drug components and disease targets. Then, PPI networks were constructed using the STRING website. R software was used for GO and KEGG enrichment analyses. Cytoscape software was used for topological analyses, and AutoDock Vina v.1.1.2 software was used for molecular docking. 64 compounds corresponding to four drugs were found by the TCMSP database, 1001 total drug targets were found by the PubChem database, 607 wet AMD target genes were found by the GEO, DisGeNET, and GeneCards databases, and 87 Xueshuantong target genes for wet AMD were obtained. Then, by constructing the drug component and disease target network and PPI network, we found that the components closely interacted with VEGF, TNF, caspase 3, CXCL8, and AKT1, which suggested that the therapeutic effects might be related to the inhibition of neovascularization, inflammation, and AKT pathway. Then, GO enrichment analysis showed that the biological processes response to hypoxia, positive regulation of angiogenesis, and inflammatory response were enriched. KEGG enrichment results showed that the HIF-1 and pi3k-akt pathways may mediate the inhibition of wet AMD by Xueshuantong. Topological analysis results identified 10 key proteins, including VEGF, TNF, AKT1, and TLR4. The results of molecular docking also confirmed their strong binding to their respective compounds. In this study, it was confirmed that Xueshuantong could inhibit wet AMD by targeting VEGF, TNF, TLR4, and AKT1, multichannel HIF-1, and the PI3K-AKT pathway, which further proved the therapeutic effects of Xueshuantong combined with single anti-VEGF therapy on wet AMD and provided new insights into the study of novel molecular drug targets for the treatment of wet AMD.

Indexed as

Drugs, Chinese HerbalMolecular Docking SimulationNetwork PharmacologyWet Macular DegenerationHumansProtein Interaction MapsVascular Endothelial Growth Factor ADrugs, Chinese HerbalVascular Endothelial Growth Factor ANetwork pharmacologyNew therapeutic targetOcular mechanismWet age-related macular degenerationXueshuantong

Identifiers

PMID38383835
OpenAlexW4392017143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.